Phase 2, Double-Blind, Placebo Controlled Clinical Trial of EPI-743 in Subjects With Cobalamin C Defect
Phase of Trial: Phase II
Latest Information Update: 27 Apr 2017
Price : $35 *
At a glance
- Drugs Vatiquinone (Primary)
- Indications Homocystinuria; Methylmalonic acidaemia
- Focus Therapeutic Use
- 22 Apr 2017 Status changed from active, no longer recruiting to completed.
- 23 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Feb 2014 New trial record